BR112015023435A8 - formulações mastigáveis e seus métodos de manufatura - Google Patents

formulações mastigáveis e seus métodos de manufatura Download PDF

Info

Publication number
BR112015023435A8
BR112015023435A8 BR112015023435A BR112015023435A BR112015023435A8 BR 112015023435 A8 BR112015023435 A8 BR 112015023435A8 BR 112015023435 A BR112015023435 A BR 112015023435A BR 112015023435 A BR112015023435 A BR 112015023435A BR 112015023435 A8 BR112015023435 A8 BR 112015023435A8
Authority
BR
Brazil
Prior art keywords
chewable formulation
composition
lipid
fat
formulation
Prior art date
Application number
BR112015023435A
Other languages
English (en)
Other versions
BR112015023435B1 (pt
BR112015023435A2 (pt
Inventor
Anthony Gill David
Robert Cleverly Douglas
Devaraj Gopinath
Davies Keryn
Agarwal Priyanka
Win Su
Original Assignee
Argenta Mfg Limited
Anthony Gill David
Robert Cleverly Douglas
Devaraj Gopinath
Davies Keryn
Agarwal Priyanka
Win Su
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51535990&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015023435(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Argenta Mfg Limited, Anthony Gill David, Robert Cleverly Douglas, Devaraj Gopinath, Davies Keryn, Agarwal Priyanka, Win Su filed Critical Argenta Mfg Limited
Publication of BR112015023435A2 publication Critical patent/BR112015023435A2/pt
Publication of BR112015023435A8 publication Critical patent/BR112015023435A8/pt
Publication of BR112015023435B1 publication Critical patent/BR112015023435B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/158—Fatty acids; Fats; Products containing oils or fats
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/168—Steroids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/179—Colouring agents, e.g. pigmenting or dyeing agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/184—Hormones
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/195—Antibiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/10—Shaping or working-up of animal feeding-stuffs by agglomeration; by granulation, e.g. making powders
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/20—Shaping or working-up of animal feeding-stuffs by moulding, e.g. making cakes or briquettes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/25—Shaping or working-up of animal feeding-stuffs by extrusion
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K40/00—Shaping or working-up of animal feeding-stuffs
    • A23K40/30—Shaping or working-up of animal feeding-stuffs by encapsulating; by coating
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A23K50/42—Dry feed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Husbandry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Anesthesiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"formulação mastigável" a presente invenção refere-se a uma formulação mastigável para a entrega de um agente nutrional ou farmaceuticamente ativo para um animal alvo. a formulação mastigável compreende um ingrediente nutricional ou uma quantidade eficaz de um agente farmaceuticamente ativo e um plastificante. a formulação mastigável é formada por extrusão e a formulação substancialmente não contém água não ligada, nem é adicionada água no processo de fabricação. a presente invenção também se refere a um método de fabricação de uma formulação mastigável com vida de prateleira estável que compreende a mistura do agente nutricional ou farmaceuticamente ativo com uma gordura, lipídeo ou gordura e lipídeo para obter uma primeira composição, a adição de um ou mais plastificantes a primeira mistura para se obter uma segunda composição, a extrusão da segunda composição a uma temperatura suficiente para derreter a gordura e lipídeo, e permitindo que a segunda composição extrusada esfriar até temperatura ambiente proporcionando, desse modo, a formulação mastigável.
BR112015023435-6A 2013-03-15 2014-03-17 Formulação mastigável estável sob armazenagem e método de fabricação de uma formulação mastigável, palatável e estável sob armazenagem BR112015023435B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793676P 2013-03-15 2013-03-15
US61/793,676 2013-03-15
PCT/IB2014/059911 WO2014141223A1 (en) 2013-03-15 2014-03-17 Chewable formulation

Publications (3)

Publication Number Publication Date
BR112015023435A2 BR112015023435A2 (pt) 2017-07-18
BR112015023435A8 true BR112015023435A8 (pt) 2019-12-03
BR112015023435B1 BR112015023435B1 (pt) 2022-05-03

Family

ID=51535990

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023435-6A BR112015023435B1 (pt) 2013-03-15 2014-03-17 Formulação mastigável estável sob armazenagem e método de fabricação de uma formulação mastigável, palatável e estável sob armazenagem

Country Status (8)

Country Link
US (2) US9314478B2 (pt)
EP (1) EP2968569A4 (pt)
JP (2) JP6378702B2 (pt)
CN (2) CN105451771B (pt)
AU (5) AU2014229179C1 (pt)
BR (1) BR112015023435B1 (pt)
CA (1) CA2906295C (pt)
WO (1) WO2014141223A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141223A1 (en) * 2013-03-15 2014-09-18 Argenta Manufacturing Limited Chewable formulation
DE202014006415U1 (de) * 2014-08-12 2015-11-13 Boehringer Ingelheim International Gmbh Wasserlösliches Granulat zur Herstellung einer Trinklösung
WO2016073347A1 (en) * 2014-11-03 2016-05-12 Zoetis Services Llc Palatable chewable veterinary composition
US9808010B2 (en) 2015-07-06 2017-11-07 Virbac Corporation Chewable composition
EP3308773A1 (en) * 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulations of cysteamine and cysteamine derivatives
DE18837223T1 (de) 2017-07-26 2020-03-26 Tgx Soft Chew, Llc Stärkefreier weicher kausnack für veterinärmedizinische anwendungen
US12115135B2 (en) * 2018-04-11 2024-10-15 Richard Postrel Anti-aging therapy for canines and other domesticated animals
AU2018379448A1 (en) 2017-12-08 2020-03-12 F. Hoffmann-La Roche Ag Pharmaceutical formulation
AR116524A1 (es) * 2018-10-04 2021-05-19 Elanco Tiergesundheit Ag Potenciación de tratamiento de helmintos
US20200146318A1 (en) * 2019-09-27 2020-05-14 Société des Produits Nestlé S.A. Edible chew for a human child and methods of making and using the edible chew
EP3878436A1 (en) 2020-03-09 2021-09-15 Bayer Animal Health GmbH Soft chewable formed body for the administration to animals
US20230180795A1 (en) * 2020-05-06 2023-06-15 Mars, Incorporated Palatable support compositions for administration of medicinal products
EP4322766A1 (en) * 2021-04-15 2024-02-21 Givaudan SA Taste modifier
NL2028708B1 (en) * 2021-07-13 2023-01-18 Stabican B V Process for preparing cannabinoid-containing particles
FR3138315A1 (fr) 2022-07-27 2024-02-02 Virbac Produit à usage vétérinaire et procédé pour sa fabrication

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2857897B2 (ja) * 1989-12-11 1999-02-17 株式会社山海 膨化成形食品
US5380535A (en) 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
US5296209A (en) 1992-01-17 1994-03-22 Colgate Palmolive Company Pet chew product having oral care properties
ES2167436T3 (es) 1994-05-20 2002-05-16 Janssen Pharmaceutica Nv Tabletas de flubendazol masticables para animales de compañia.
CN1188646A (zh) * 1997-01-24 1998-07-29 赫彻斯特股份公司 制备味道被掩盖的抗菌活性的喹喏酮衍生物制剂
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
US6387381B2 (en) * 1998-09-24 2002-05-14 Ez-Med Company Semi-moist oral delivery system
US6672252B2 (en) 2002-01-31 2004-01-06 Sergeant's Pet Products, Inc. Pet chew
US20050271708A1 (en) 2002-03-05 2005-12-08 Thombre Avinash G Palatable controlled-release formulation for companion animals
US20040151759A1 (en) 2002-08-16 2004-08-05 Douglas Cleverly Non-animal product containing veterinary formulations
US20040037869A1 (en) 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
EP1440622B1 (en) * 2003-01-27 2014-03-05 Nestec S.A. Use of expanded constituents and manufacture of products therefrom
AU2008201605B2 (en) 2003-07-30 2010-04-29 Novartis Ag Palatable ductile chewable veterinary composition
TWI366442B (en) 2003-07-30 2012-06-21 Novartis Ag Palatable ductile chewable veterinary composition
EP1523892A1 (en) 2003-10-17 2005-04-20 Paragon Products B.V. i.o. Pet's chew
BRPI0509673A (pt) 2004-04-07 2007-10-09 Intervet Int Bv composição para o tratamento de parasitas, forma de dosagem farmacêutica, método para tratar um organismo, e, processos para introduzir pelo menos um aditivo em um organismo, para fabricar uma composição, para liberar um aditivo em um organismo, e, para conformar um produto macio mastigável
EP1602285A1 (en) 2004-06-04 2005-12-07 Gaines Treats Limited A process for preparing a chewable pet food
CA2601677A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US7348027B2 (en) 2005-04-08 2008-03-25 Bayer Healthcare Llc Taste masked veterinary formulation
US20070148282A1 (en) 2005-12-02 2007-06-28 Mars, Inc. Performance Oral Snack
US20070128251A1 (en) 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US7955632B2 (en) 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
EP1800545A1 (en) 2005-12-23 2007-06-27 Nestec S.A. Pet food and processes of producing the same
ES2303446B1 (es) 2006-07-03 2009-07-28 Viscofan, S.A. Producto masticable y/o comestible para mascotas y animales.
EP2063869B1 (en) 2006-09-07 2014-03-05 Merial Ltd. Soft chewable veterinary antibiotic formulations
US8455025B2 (en) 2010-04-21 2013-06-04 Petmatrix LLC Edible pet chew made from a single initially malleable sheet
JP2010518845A (ja) * 2007-02-26 2010-06-03 リヴォリマー リミテッド 薬用チューインガム
RU2476076C2 (ru) * 2007-02-26 2013-02-27 Револимер Лимитед Лечебная жевательная резинка
WO2008134819A1 (en) * 2007-05-07 2008-11-13 Jurox Pty Ltd Improved dosage form and process
US20080293645A1 (en) 2007-05-25 2008-11-27 Schneider Lawrence F Antiparasitic combination and method for treating domestic animals
MX2009013021A (es) * 2007-06-01 2010-01-20 Cadbury Adams Usa Llc Composiciones de goma con relleno que incorporan triacetina.
AU2008261793A1 (en) 2007-06-13 2008-12-18 E. I. Du Pont De Nemours And Company Isoxazoline insecticides
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
WO2009007770A1 (en) * 2007-07-06 2009-01-15 Gumlink A/S Chewing gum granules for compressed chewing gum
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
US10668012B2 (en) 2008-09-04 2020-06-02 Farnam Companies, Inc. Chewable sustained release formulations
WO2010030944A2 (en) * 2008-09-12 2010-03-18 Solae, Llc Functional food paste
WO2010063387A1 (de) * 2008-12-05 2010-06-10 Bayer Animal Health Gmbh Extrudate mit nadelförmigen wirkstoffen
MA34247B1 (fr) 2010-05-27 2013-05-02 Du Pont Forme cristalline du 4-[5-[3-chloro-5-(trifluorométhyl) phényl] -4,5-dihydro-5-(trifluorométhyl)-3-isoxazolyl]-n-[2-oxo-2-[(2, 2,2-trifluoroéthyl) amino] éthyl]-1-naphtalènecarboxamide
PT2755473T (pt) 2011-09-12 2019-03-25 Boehringer Ingelheim Animal Health Usa Inc Composições parasiticidas compreendendo um agente ativo de isoxazolina, métodos e suas utilizações
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2013119442A1 (en) * 2012-02-06 2013-08-15 Merial Limited Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
WO2014141223A1 (en) * 2013-03-15 2014-09-18 Argenta Manufacturing Limited Chewable formulation

Also Published As

Publication number Publication date
CN105451771A (zh) 2016-03-30
EP2968569A4 (en) 2016-11-02
US20150190417A1 (en) 2015-07-09
CN111803465A (zh) 2020-10-23
EP2968569A1 (en) 2016-01-20
JP6841799B2 (ja) 2021-03-10
CA2906295A1 (en) 2014-09-18
AU2014229179C1 (en) 2018-09-27
BR112015023435B1 (pt) 2022-05-03
JP2018162326A (ja) 2018-10-18
AU2017221825A1 (en) 2017-11-09
US20160184223A1 (en) 2016-06-30
CA2906295C (en) 2019-01-22
BR112015023435A2 (pt) 2017-07-18
CN111803465B (zh) 2023-05-09
JP6378702B2 (ja) 2018-08-22
AU2020277251A1 (en) 2020-12-24
US9597285B2 (en) 2017-03-21
JP2016512229A (ja) 2016-04-25
AU2014229179B2 (en) 2017-09-14
CN105451771B (zh) 2020-05-19
US9314478B2 (en) 2016-04-19
AU2014229179A1 (en) 2015-10-08
AU2023200668A1 (en) 2023-03-09
AU2019203788A1 (en) 2019-06-20
WO2014141223A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
BR112015023435A8 (pt) formulações mastigáveis e seus métodos de manufatura
WO2014167554A3 (en) Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
CL2020001972A1 (es) Ingredientes de pienso que comprenden células microbianas lisadas. (divisional solicitud 201803797)
BR112014019262A8 (pt) Composições orais veterinárias parasíticas compreendendo ingredientes ativos de ação sistêmica, métodos e uso das mesmas
CL2019001447A1 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos.
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
BR112013010524A2 (pt) dispersões sólidas extrusadas por fusão contendo um agente indutor de apoptose
RU2011134420A (ru) Жидкие композиции, способные к пенообразованию и включающие активные средства, и способы их получения и разработки
BRPI1013723A8 (pt) Composição alimentar para ruminante, e, métodos de suplementação da dieta de um ruminante com lisina e de produção de uma composição alimentar para ruminante
NZ709486A (en) Solid solution compositions and use in chronic inflammation
BR112015023658A2 (pt) formulação de vitamina d de liberação modificada, estabilizada e método de administração desta
JP2011126882A5 (pt)
BR0215421A (pt) Processo para a preparação de um sistema de distribuição de ingrediente ou composição hidrófoba granular, e, sistema de distribuição granular
BR112012026223A2 (pt) formulação adequada para o uso em ração animal, uso, e ração para animais.
PE20191492A1 (es) Composicion farmaceutica que comprende selexipag
AR097146A1 (es) Composición para alimentación de rumiantes y método para prepararla
AR105144A1 (es) Composiciones nutricionales y métodos para promover el desarrollo cognitivo
IL251413B1 (en) Composition of injectable buprenorphine
BR112017007428A2 (pt) composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença
WO2016123430A3 (en) Method for preparing a delivery system of one or more active ingredients in an edible composition
BR112019005704A2 (pt) processo para preparar um alimento em gel para um animal, composição de alimento gelificada, alimento gelificado, agente gelificante, e, método para alimentar um animal.
AR094770A1 (es) Composición masticable para administración oral y proceso para preparar la misma
CR20150508A (es) Formulaciones veterinarias estables de combinación de lactonas macrocíclicas e imidazotiazoles
BR112019002285A2 (pt) composição antimicrobiana
AR097148A1 (es) Composición alimenticia para rumiantes y método para prepararla

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2014, OBSERVADAS AS CONDICOES LEGAIS.